Novartis grabs lead IL-17 program as Ensemble adds another marquee deal

John Carroll FierceBiotech News

Novartis: No data-tampering in retracted Diovan study

Tracy Staton Former Novartis employees did work on Diovan trials in Japan and didn't disclose their relationships with the company in the studies, the company says. But Novartis ...

CHMP Grants Novartis Ultibro Breezhaler Positive Opinion

mia.burns Novartis first in class once-daily dual bronchodilator Ultibro® Breezhaler® (QVA149) gains positive CHMP opinion for the treatment of COPD   QVA149 (indacaterol/glycopyrronium) ...

Novartis COPD drug gets European backing

Emily Mullin Swiss pharma giant Novartis has earned an endorsement from the European Committee for Medicinal Products for Human Use for it once-daily Ultibro Breezhaler to treat chronic ...

Novartis’ Bexsero left off U.K. immunization schedule

Carly Helfand Novartis' Bexsero may be the only vaccine approved for life-threatening meningitis B, but that wasn't enough to convince the U.K.'s Joint Committee on Vaccination ...

Report: AstraZeneca, Pfizer, Novartis home in on Onyx bids

Tracy Staton AstraZeneca, Novartis and Pfizer are still in the hunt for Onyx Pharmaceuticals, Bloomberg's sources say. And Amgen, which triggered the whole bidding process with ...

AstraZeneca, Pfizer, Novartis courting Onyx

Emily Mullin After Amgen pulled the trigger on the bid for Onyx Pharmaceuticals, AstraZeneca, Novartis and Pfizer also are reportedly vying for chance to scoop up the company in an ...

Novartis buries a PhIII kidney cancer failure behind Q2 successes

John Carroll In a terse summary, Novartis noted: "Results of the Phase III trial evaluating the investigational therapy TKI258 showed the drug did not meet its primary endpoint ...

Novartis under U.S. scrutiny for Gilenya marketing tactics

Tracy Staton Novartis is up against another marketing investigation. A U.S. Attorney's Office in New York has demanded documents and information about its Gilenya promotions, adding ...

Feds Probe Novartis Over Marketing Of Its Gilenya MS Pill

esilverman YOU READ IT HERE FIRST: Novartis marketing is under a microscope. The US Attorney in New York has issued a civil investigative demand to the drugmaker for documents ...

Novartis raises guidance thanks to no-show Diovan generic

Carly Helfand Why exactly a generic version of Novartis' blood-pressure drug Diovan has yet to hit the market is a bit of a mystery, but one thing is clear: The company is benefiting ...

Novartis ex-chair Vasella nets new $5.2M exit package

Tracy Staton Daniel Vasella has a new exit package, and at a total of 5 million francs, it's a small fraction of the 72 million originally approved by the Novartis board. But at ...
Page 10 of 14« First...89101112...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS